Skip to main content
padlock icon - secure page this page is secure

End‐stage renal disease patients using angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers may reduce the risk of mortality: a Taiwanese Nationwide cohort study

Buy Article:

$52.00 + tax (Refund Policy)

The association between the use of angiotensin‐converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) and mortality in end‐stage renal disease (ESRD) patients lacks sufficient evidence.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: angiotensin receptor blocker; angiotensin‐converting enzyme inhibitor; end‐stage renal disease; mortality

Document Type: Research Article

Publication date: September 1, 2018

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more